SPRO Quote, Financials, Valuation and Earnings

Dare Bioscience has a net margin of -271.3% compared to Spero Therapeutics's net margin of -17219.13%. Spero Therapeutics's return on equity of -108.26% beat Dare Bioscience's return on equity of --.

Spero Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 102.43%. On the other hand Dare Bioscience has an analysts' consensus of $13.00 which suggests that it could grow by 396.18%. Given that Dare Bioscience has higher upside potential than Spero Therapeutics, analysts believe Dare Bioscience is more attractive than Spero Therapeutics.

Spero Therapeutics has a beta of 1.331, which suggesting that the stock is 33.062% more volatile than S&P 500. In comparison Dare Bioscience has a beta of 1.138, suggesting its more volatile than the S&P 500 by 13.754%.

Spero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dare Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics pays -- of its earnings as a dividend. Dare Bioscience pays out -- of its earnings as a dividend.

Spero Therapeutics quarterly revenues are $5.1M, which are larger than Dare Bioscience quarterly revenues of $25.4K. Spero Therapeutics's net income of -$13.9M is lower than Dare Bioscience's net income of -$4.4M. Notably, Spero Therapeutics's price-to-earnings ratio is 10.75x while Dare Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics is 4.76x versus 854.30x for Dare Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Macrogenics has a net margin of -271.3% compared to Spero Therapeutics's net margin of -311.07%. Spero Therapeutics's return on equity of -108.26% beat Macrogenics's return on equity of -58.23%.

Spero Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 102.43%. On the other hand Macrogenics has an analysts' consensus of $4.20 which suggests that it could grow by 176.32%. Given that Macrogenics has higher upside potential than Spero Therapeutics, analysts believe Macrogenics is more attractive than Spero Therapeutics.

Spero Therapeutics has a beta of 1.331, which suggesting that the stock is 33.062% more volatile than S&P 500. In comparison Macrogenics has a beta of 1.587, suggesting its more volatile than the S&P 500 by 58.67%.

Spero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Macrogenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics pays -- of its earnings as a dividend. Macrogenics pays out -- of its earnings as a dividend.

Spero Therapeutics quarterly revenues are $5.1M, which are smaller than Macrogenics quarterly revenues of $13.2M. Spero Therapeutics's net income of -$13.9M is higher than Macrogenics's net income of -$41M. Notably, Spero Therapeutics's price-to-earnings ratio is 10.75x while Macrogenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics is 4.76x versus 0.63x for Macrogenics. Usually stocks with elevated PS ratios are considered overvalued.

Puma Biotechnology has a net margin of -271.3% compared to Spero Therapeutics's net margin of 6.46%. Spero Therapeutics's return on equity of -108.26% beat Puma Biotechnology's return on equity of 52.9%.

Spero Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 102.43%. On the other hand Puma Biotechnology has an analysts' consensus of $3.00 which suggests that it could fall by -12.79%. Given that Spero Therapeutics has higher upside potential than Puma Biotechnology, analysts believe Spero Therapeutics is more attractive than Puma Biotechnology.

Spero Therapeutics has a beta of 1.331, which suggesting that the stock is 33.062% more volatile than S&P 500. In comparison Puma Biotechnology has a beta of 1.287, suggesting its more volatile than the S&P 500 by 28.736%.

Spero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics pays -- of its earnings as a dividend. Puma Biotechnology pays out -- of its earnings as a dividend.

Spero Therapeutics quarterly revenues are $5.1M, which are smaller than Puma Biotechnology quarterly revenues of $46M. Spero Therapeutics's net income of -$13.9M is lower than Puma Biotechnology's net income of $3M. Notably, Spero Therapeutics's price-to-earnings ratio is 10.75x while Puma Biotechnology's PE ratio is 4.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics is 4.76x versus 0.73x for Puma Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -271.3% compared to Spero Therapeutics's net margin of 23.33%. Spero Therapeutics's return on equity of -108.26% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Spero Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 102.43%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.30 which suggests that it could grow by 6.55%. Given that Spero Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Spero Therapeutics is more attractive than Vertex Pharmaceuticals.

Spero Therapeutics has a beta of 1.331, which suggesting that the stock is 33.062% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.044%.

Spero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Spero Therapeutics quarterly revenues are $5.1M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Spero Therapeutics's net income of -$13.9M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Spero Therapeutics's price-to-earnings ratio is 10.75x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics is 4.76x versus 10.96x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.